SCYNEXIS ($SCYX) Stock Hub: Can SCY-770 and BARDA-Backed SCY-247 Both Reach Phase 2?

01 Full constructive and adverse scenarios

Constructive scenario: execution gives the funding strategic value

The strongest case starts with a practical change: SCYNEXIS can advance its antifungal program with a government partner while continuing to prioritize SCY-770. BARDA now provides a defined base period and a route to later options, which can reduce the pressure to finance every eligible development dollar by selling shares, provided the company meets the contract’s conditions and controls its own share of spending.

The clinical version of this case requires more than a favorable headline. SCY-247’s IV study must support a usable dosing regimen and later patient data must show activity with acceptable safety; SCY-770 must translate its biological rationale and prior human exposure into renal evidence. A successful GSK relaunch would add a separate commercial stream, but it should not be needed to make near-term cash arithmetic work.

Adverse scenario: financial support does not resolve clinical uncertainty

A funded development program can still fail. Safety, exposure, efficacy, manufacturing or enrollment could disappoint; BARDA may not exercise later options. The historical SCY-770 trial in fatty liver disease missed its primary placebo comparison, which does not determine ADPKD outcomes but does rule out treating the compound as clinically validated for kidney disease.

Investors can also be diluted while the science improves. Pre-funded instruments are economic exposure already outstanding, and common warrants and equity compensation can enlarge the share base later. A conditional contract ceiling is not a liquidation-value floor, so a milestone can lift the stock while per-share uncertainty stays high.

Intermediate scenario: useful milestones, slower proof

Informative Phase 1 readouts, now past their Q3 window, followed by a Phase 2 start in the fourth quarter would move the programs forward without answering the main efficacy question. Enrollment, dose choice and a credible analysis plan become the next tests; passing a development milestone is not equivalent to earning an approval. These are analytical scenarios, without assigned probabilities, price targets or trading recommendations.

BARDA award · Q2 Form 10-Q: clinical and financing risks

What Would Falsify This Reading

The reading presented here is that SCYNEXIS can fund two programs into Phase 2: SCY-770 in ADPKD on its own balance sheet, with runway guided into 2029, and SCY-247 in invasive candidiasis with BARDA sharing the cost. Each observation below would contradict that reading and can be checked against a primary source.

• A Phase 1 result that changes the SCY-770 dose plan. Exposure or gastrointestinal tolerability at 750 mg once daily or 500 mg twice daily that cannot support the planned ADPKD doses would put the Q4 2026 Phase 2 start and the 2027 early readout in question.
• No SCY-770 Phase 2 start by December 31, 2026. A start outside the guided fourth quarter would remove the timeline this reading relies on; the start also triggers the $2M Poxel milestone.
• Weaker runway language in the Q3 Form 10-Q. A runway shorter than into 2029, or an equity raise before patient data, would mean SCY-247 cost sharing or SCY-770 spending is heavier than planned.
• Contract terms that differ from the summary. A narrow eligible-cost base, a cost share weighted toward SCYNEXIS or conditions that make option exercise unlikely in the redacted contract would weaken the funding case.
• An intravenous SCY-247 safety or exposure problem. Infusion tolerability issues or exposure below the oral target would complicate the oral and IV Phase 2 plan that the BARDA base period is meant to fund.

None of these is a prediction. They are the observations that would make the rest of this analysis wrong, listed so that a reader can check them rather than take the reading on trust.

02 Catalyst map: what happens next and why

The dates below distinguish management guidance from fixed events. The BARDA contract, signed September 25 and announced September 28, is an accomplished event; future work under it is the catalyst. The original Q3 Phase 1 windows elapsed September 30. SCY-770 completion was subsequently announced October 6; no SCY-247 IV topline had been released as of October 6. Impact levels are Merlintrader’s qualitative assessment, not a forecast of the share-price move.

No PDUFA date exists for SCY-770 or SCY-247, and registry completion estimates are not company-announced readout dates. SEC Q2 guidance · September 28 update

03 SCYNEXIS: two development paths with different economics

SCYNEXIS is rebuilding its investment case around severe rare diseases. The acquisition of Poxel’s direct AMPK activator program in March 2026 brought in PXL770, now SCY-770, and made autosomal dominant polycystic kidney disease, or ADPKD, the lead development opportunity. The September 28, 2026 BARDA award adds a second development driver by supporting SCY-247. Kidney disease remains the lead program, while the antifungal portfolio gains a more concrete financing route.

The portfolio now has three distinct economic roles. SCY-770 requires the company to establish clinical benefit in ADPKD. SCY-247 is a wholly owned antifungal candidate whose oral and intravenous formulations could support a hospital treatment strategy. BREXAFEMME is an approved product licensed to GSK, with potential future royalties and sales milestones dependent on the partner’s commercial execution.

The strategic attraction is diversification across mechanisms and markets; the challenge is that a small organization must split clinical, manufacturing and financial resources between programs with different requirements. A dose-selection study can move a program forward without showing that it works in patients, and a partner’s relaunch can create income without validating the rest of the pipeline.

Sources: SCYNEXIS Q2 2026 Form 10-Q; official strategic collaborations; September 28 BARDA award.

04 SCY-770: testing AMPK activation in ADPKD

ADPKD is an inherited disorder in which fluid-filled cysts progressively enlarge the kidneys and can impair their function. The clinical objective is to slow that progression before patients reach kidney failure.

SCY-770 is an oral small molecule that directly activates AMP-activated protein kinase, or AMPK, an important regulator of cellular energy handling. The development hypothesis is that this mechanism can influence several processes involved in cyst growth, including abnormal metabolism, cell proliferation and inflammatory signaling. Preclinical findings support testing the approach, but they do not establish a treatment effect in people with ADPKD.

Two measurements matter. Height-adjusted total kidney volume, or htTKV, uses imaging to follow kidney enlargement; estimated glomerular filtration rate, or eGFR, measures kidney function. An early imaging signal could make the hypothesis more credible, while durable preservation of function is the more direct indication of clinical benefit.

The commercial possibility is an additional disease-modifying option with a different mechanism from established therapy. It depends on an exposure that patients tolerate over time and a reproducible effect. Experience with the same molecule in another disease provides safety information without establishing the dose, population or duration appropriate for ADPKD.

Sources: SCYNEXIS SCY-770 scientific overview; March 31, 2026 investor presentation.

05 SCY-770 clinical evidence: what is established and what comes next

The previous clinical experience with PXL770 is useful but requires a clear boundary. In the published STAMP-NAFLD Phase 2a trial, 120 participants received one of three oral dosing regimens or placebo for 12 weeks. The study did not meet its primary endpoint of liver-fat improvement versus placebo. Diarrhea occurred in 17%–23% of active-treatment participants and in none receiving placebo; the publication reported no life-threatening events or treatment-related deaths. Metabolic signals generated further hypotheses, but neither those signals nor the overall tolerability findings demonstrate efficacy in ADPKD.

The current Phase 1 program, registered in two Australian entries, tests how food and repeated dosing affect exposure in healthy volunteers, with safety and tolerability as primary assessments.

The food-effect record was last updated on June 25, 2026 and lists nine participants accrued against a target of nine. The repeated-dose record was updated on August 28, reported eight participants accrued toward the target of sixteen and gave September 2, 2026 as the anticipated date of last data collection. Rechecked on October 2, both records still showed recruiting status and the same update dates; an anticipated date in a registry is not confirmation that data collection finished.

The planned ADPKD Phase 2 design shown in the March presentation included 50 participants: twenty in each of two active-dose groups and ten receiving placebo. A 16-week blinded period would be followed by 32 weeks of open-label treatment. Planned assessments included htTKV, eGFR and additional renal or biological measurements. The proposed population comprised adults aged 18–55 with rapidly progressing imaging categories, eGFR of 45–90 and no tolvaptan use. This is a company-described plan, not a finalized registry protocol.

On August 10, management retained a Q3 2026 Phase 1 topline window, Q4 2026 Phase 2 initiation and an early efficacy readout in the second half of 2027. Completion of the Phase 1 study was announced October 6, after the original quarterly window, and the Phase 2 start remained guided to Q4. The healthy-volunteer result supports dose selection; the patient study must then show an effect large and consistent enough to justify further development.

The SCY-770 Phase 1 result came on October 6, 2026, six days after the quarter closed. SCYNEXIS announced completion of the study in 25 healthy participants across three cohorts: a single 500 mg dose under fed and fasted conditions, then 750 mg once daily or 500 mg twice daily, or placebo, for seven days. The company reported that SCY-770 was well tolerated at doses higher than previously evaluated, with a safety profile consistent with prior experience, and that pharmacokinetic data from this and earlier studies will inform the Phase 2 dose; the release gives no exposure figures. The ADPKD Phase 2 proof-of-concept study remains guided to start in the fourth quarter of 2026. Source → No SCY-247 intravenous Phase 1 topline had been released by October 6.

Sources: published STAMP-NAFLD results; food-effect registry; repeated-dose registry; planned Phase 2 design, slide 13; August 10, 2026 update.

06 SCY-247: BARDA support strengthens the route into patient trials

SCY-247 is SCYNEXIS’s second-generation fungerp, a triterpenoid antifungal targeting glucan synthesis, aimed at severe invasive fungal infections including difficult-to-treat organisms. Laboratory and animal findings justify development; they do not show that the candidate will overcome resistance or improve outcomes in patients.

The oral Phase 1 SAD/MAD results announced on September 30, 2025 included 66 healthy participants receiving SCY-247 and 22 receiving placebo. No serious or severe treatment-emergent adverse events were reported. Headache occurred in 16.7% versus 4.5%, while diarrhea was reported in 9% of each group. One participant stopped because of an adverse event considered unrelated to treatment. The 200 mg and 300 mg once-daily regimens reached or exceeded a preliminary exposure target derived from preclinical invasive-candidiasis models.

That exposure result bridges preclinical work and patient trials; it is not evidence that infections were treated, and healthy volunteers cannot predict tolerability in severely ill patients with organ dysfunction and multiple medications.

The company announced first dosing in the intravenous Phase 1 study on February 26, 2026, and on September 28 confirmed completed dosing with analysis ongoing. The Q3 2026 topline window closed on September 30 without a disclosed result as of October 2, and no new date has been given. An intravenous option could support initial hospital treatment and an oral option later step-down, so useful exposure with both formulations matters to the intended product profile.

BARDA’s base period provides approximately $18.5 million to take oral and IV SCY-247 into Phase 2. The maximum of approximately $214 million requires all options to be exercised over a period of up to ten years and could fund work through NDA submissions for invasive-candidiasis treatment and prevention of invasive fungal infections in high-risk patients. The Form 8-K filed on September 28 adds that the contract was signed on September 25, that the base period commences in September 2026 and that the balance depends on up to six options. The company called SCY-247 a Phase-2 ready program, and chief executive David Angulo said the partnership allows SCYNEXIS to advance two programs into Phase 2.

The August filing anticipated a possible Phase 2 start in the first half of 2027; the award addresses the financing question but gives no replacement start date, and SCYNEXIS retains its share of program costs.

Sources: SCY-247 scientific overview; oral Phase 1 results; IV study initiation; Q2 Form 10-Q: updated Phase 2 timing; BARDA contract announcement; BARDA Form 8-K.

07 BREXAFEMME and GSK: commercial optionality after MARIO

BREXAFEMME, or ibrexafungerp, remains a different proposition from the investigational pipeline. Its approved US indications are treatment of vulvovaginal candidiasis and reduction in the incidence of recurrent vulvovaginal candidiasis. The July 2026 FDA label identifies GSK and retains a boxed warning for embryo-fetal toxicity, including a contraindication in pregnancy. Regulatory approval and an updated label do not, by themselves, demonstrate that a commercial relaunch has occurred.

The manufacturing disruption originated in a potential cross-contamination risk involving a non-antibacterial beta-lactam drug substance. The FDA’s September 2023 notice concerned two recalled lots; it did not describe bacterial contamination. The clinical hold was subsequently lifted in April 2025. Nevertheless, the later agreement with GSK ended the MARIO development effort. The NDA transfer to GSK was completed in November 2025, leaving the partner central to any commercial restart.

MARIO’s registry now records termination for a strategic decision, described by the sponsor as unrelated to safety or efficacy concerns. Only 68 participants were enrolled against a target of 220. Results posted on August 10, 2026 report day-30 deaths of four among 36 participants assigned to ibrexafungerp step-down therapy and three among 32 assigned to the comparator strategy, with five outcomes unknown. The independent review needed for the global-response endpoint was canceled. Missing endpoint data are not zero responses, and the truncated study cannot establish a reliable comparative conclusion.

FURI and CARES are historical, single-arm studies of ibrexafungerp, not SCY-247. FURI enrolled 233 participants with refractory or treatment-intolerant fungal diseases; the registry reports 142 global-response successes, 69 failures and 22 non-evaluable outcomes. CARES enrolled thirty people with Candida auris infection and reported twenty-one global successes. Deaths reported in these seriously ill populations cannot automatically be attributed to treatment or used for uncontrolled comparisons.

The economic opportunity therefore depends on execution outside SCYNEXIS’s direct commercial control. The NDA-transfer announcement described potential sales milestones of up to $145.5 million and low-to-mid-single-digit royalties net of payments to Merck. These are contingent future receipts. They are not existing cash, a guaranteed revenue stream or evidence that the abandoned MARIO indication will return.

One dated sign of GSK’s stewardship sits on the trial registry. ClinicalTrials.gov lists GSK as sponsor of NCT05908682, an observational study of people exposed to ibrexafungerp during pregnancy, with infant outcomes followed for up to one year. The record, last updated on September 23, 2026, shows recruiting status, an actual start on November 12, 2025, an estimated 100 participants and estimated completion on July 31, 2029. It is pregnancy-safety work under the boxed warning, not a launch announcement.

Sources: FDA label, July 2026; FDA recall notice; 2025 Form 10-K; MARIO; GSK pregnancy-safety study; FURI; CARES; NDA transfer and commercial economics.

08 Competition and the regulatory evidence still required

SCY-770 would enter a field with an established treatment and several development approaches. Tolvaptan, marketed as JYNARQUE, is approved to slow kidney-function decline in adults at risk of rapidly progressing ADPKD. Its liver-injury risk, monitoring and restricted distribution are burdens, but do not negate its demonstrated clinical role.

Vertex reported completed enrollment in its AGLOW Phase 2 study of VX-407 in August 2026. That 26-person, single-arm, 52-week study targets a subset of PKD1 variants and assesses htTKV. Novartis presented a proposed global Phase 3 design for farabursen, an anti-miR-17 oligonucleotide, at ERA 2026. Differences in populations, mechanisms, duration and controls prevent direct comparisons of headline imaging changes.

SCY-247 faces a separate competitive setting that includes established azoles and echinocandins. Rezafungin, marketed as REZZAYO, already provides a once-weekly intravenous option for candidemia and invasive candidiasis in patients with limited alternatives. SCY-247’s oral/IV ambition could be useful, but it must demonstrate clinical benefit and an acceptable safety profile rather than rely on laboratory activity alone. A wider comparison of listed anti-infective companies is in the Merlintrader anti-infectives overview.

Regulatory designations can facilitate development without settling these questions. SCY-770’s Orphan Drug status is not approval, and the company explicitly states that no FDA agreement has been reached on its proposed imaging-based accelerated pathway. SCY-247’s QIDP, Fast Track and Orphan designations likewise do not remove the requirement for adequate evidence. There is no confirmed PDUFA date for either candidate.

Sources: JYNARQUE FDA label; Vertex Q2 2026 update; Novartis ERA 2026 announcement; FDA REZZAYO evidence summary; SCYNEXIS regulatory and development disclosures.

09 Financial performance: cash generation and accounting earnings

SCYNEXIS’s financial statements describe a development company with irregular licensing income, rather than an established stream of commercial product sales. The $20.601 million of 2025 revenue included $19.157 million of licensing revenue and a $1.444 million adjustment to historical product revenue associated with the BREXAFEMME recall. A $17.2 million licensing catch-up followed the amended GSK agreement. The annual figure is therefore a poor base for extrapolating recurring sales.

*Q2 operating cash flow is a Merlintrader calculation: the six-month outflow less the first-quarter outflow. Individual periods retain the amounts reported in their respective filings; rounding can produce differences of $0.001 million between quarterly sums and cumulative figures. Sources: 2025 Form 10-K, Q1 Form 10-Q and Q2 Form 10-Q.

The positive Q2 net result requires particular care. A $14.152 million noncash gain from remeasuring warrant liabilities outweighed a $7.775 million operating loss. That gain generated no cash, and the first-half net loss remains $13.902 million.

The SCY-770 acquisition creates a second timing difference: its $8 million upfront cost entered Q1 research and development expense, but the payment occurred in April and raised Q2 operating cash outflow. Excluding only that payment produces $6.885 million of Q2 outflow, a Merlintrader calculation rather than a company-reported measure. The $24.8 million received from GSK likewise reduced the 2025 operating outflow, so the low annual burn is not a guide to a development quarter. FY2025 results; Q2 results.

10 Cash, balance-sheet resilience and runway

At June 30, 2026, SCYNEXIS reported $71.130 million of cash, cash equivalents and investments. That total comprises $10.487 million of cash and equivalents, $43.596 million of short-term investments and $17.047 million of longer-term investments. Restricted cash of $0.189 million is separate.

The comparable totals were $56.278 million at December 31, 2025 and $72.416 million at March 31, 2026. The March balance already included approximately $24 million of the $40 million private placement, with the remaining approximately $16 million received on April 1. Q1 balance sheet and financing note; Q2 balance sheet.

The latest management update, September 28, explicitly retains guidance that resources should fund operations into 2029. The May update had specified mid-2029; the newer wording does not identify a quarter or month. Runway is a forward-looking estimate, sensitive to trial costs and timing; dividing cash by one historical quarter would not reproduce it. September 28 runway confirmation.

The June balance sheet contains no conventional financial borrowing after repayment of the remaining $14 million convertible notes in March 2025. Total liabilities were $8.040 million, including $1.945 million of operating lease obligations and $0.796 million of warrant liabilities, and shareholders’ equity was $66.930 million. A long stated runway improves flexibility but does not finance every possible pivotal programme or rule out raising equity.

11 Capital structure, warrants and the financing clock

The latest verified cover-page count is 9,949,609 common shares outstanding on August 1, 2026, identical to the June 30 balance-sheet count. All figures below use the basis following the one-for-eight reverse split effective May 29. The comparative December 2025 count in the Q2 filing is 5,442,688; the increase to June is 82.81%, a Merlintrader calculation. Pre-split counts in earlier filings are on a different basis and are not comparable.

Source: Q2 Form 10-Q, Notes 7, 8 and 12. Instruments are not all immediately exercisable, and this table does not predict issuance.

The pre-funded total is 1,892,471. Adding it to issued common gives 11,842,080, a Merlintrader calculation showing a broader economic share base; it is not the legally outstanding common count. Separately, the filing’s 11,862,597 shares reserved for future issuance include unallocated equity-plan capacity. That figure is not outstanding warrants or certain dilution.

The March financing closed April 1 with $40.0 million gross and $36.9 million final net proceeds. Common shares and accompanying warrants were sold for a combined $7.36 per unit on the adjusted basis. Full cash exercise of the common warrants could produce another $52.2 million, but that is conditional funding. The warrants became exercisable after shareholder approval on June 25. They expire at 5 p.m. New York time on the earlier of April 1, 2031 and the thirtieth day after public release of Week 48 topline results from the SCY-770 ADPKD Phase 2 proof-of-concept trial.

The $50 million nominal Cantor ATM remains a financing channel mentioned in the Q2 filing; no ATM shares were sold through December 2025, and the nominal ceiling is not a verified amount currently available under issuance limits. The May 8 resale prospectus registers PIPE holders’ resale securities, with no company proceeds from resale itself. Nasdaq confirmed minimum-bid compliance on June 15 following the reverse split.

12 BARDA, partnership economics and contingent obligations

The September 28 BARDA award changes SCY-247’s funding position. Its initial base period provides approximately $18.5 million to support oral and intravenous development into Phase 2 invasive candidiasis. The approximately $214 million maximum requires exercise of all options, potentially over ten years. This is a cost-share arrangement covering eligible direct and general and administrative costs; SCYNEXIS expects to fund its near-term contribution within its existing plan. The Form 8-K filed the same day dates the signing to September 25 and says the company plans to file the contract, with confidential terms redacted, as an exhibit to its Q3 2026 Form 10-Q; until then, the eligible-cost definitions and cost-share percentages are not public. The award therefore adds a programme funding source, not $214 million of unrestricted cash, and management explicitly leaves runway into 2029 unchanged. September 28 BARDA announcement.

GSK offers a separate potential income stream. The October 2025 resolution produced $24.8 million of non-refundable payments and accompanied the wind-down of Phase 3 MARIO; no MARIO-specific development milestones remain payable. The remaining opportunity is up to $145.5 million of conditional milestones tied to annual net-sales thresholds, plus net royalties in the low-to-mid single digits after Merck payments: cumulative milestone opportunities, not an amount payable every year. GSK agreement in the annual report; FY2025 economics; Q2 partner update.

SCY-770 introduces obligations in the opposite direction. The Poxel acquisition required $8 million upfront, paid in April, and allows up to $8 million of additional development milestones, including $2 million upon initiation of the first Phase 2 trial. Commercial milestones can reach $180 million, with $125 million triggered at annual sales of at least $1 billion. The sales-linked maximum is contingent consideration, but the Phase 2 start has a near-term cash consequence. BARDA funding is specific to SCY-247 and cannot be assumed to cover these SCY-770 payments. Q2 acquisition note.

13 Management, governance and insider transactions

David Angulo remains President and Chief Executive Officer as the company broadens from antifungal development into rare kidney disease.

Sanjay Subramanian became CFO on September 9, 2026, with the appointment announced September 10. Ivor Macleod ceased serving as CFO on September 9 and remains with the company through October 9 to support the handover. Subramanian previously served as CFO and Head of Business Development at Inozyme and was involved in its acquisition by BioMarin. That is relevant experience, not evidence that a sale is planned. September CFO Form 8-K.

Todd Minga joined as Senior Vice President, Research & Development, effective September 14. His background includes nephrology practice and development roles at Akebia, Maze and IQVIA. Steven K. Burke joined the board effective September 18, announced September 22, bringing kidney-disease drug-development experience from Akebia. Their expertise fits SCY-770’s priority but does not substitute for controlled evidence. Minga appointment; Burke appointment.

Insider filings require careful classification. Subramanian received 100,000 options at a $4.91 strike on September 9. Burke received 5,750 RSUs and 5,750 options at a $4.46 strike on September 18. Their Form 4 transaction code is A: these are compensation grants, not open-market purchases. In contrast, Angulo participated in the March placement with 13,586 common shares and accompanying warrants, roughly $100,000 at the combined adjusted unit price. Subramanian Form 4; Burke Form 4; PIPE participation.

14 Ownership, filing limitations and analyst coverage

Institutional holdings in the SEC filings do not share a uniform denominator: beneficial ownership can include warrant shares, and exercise caps limit how many count at one time, so the percentages do not add up to an ownership total or a free-float estimate.

Sources: CVI/Heights Schedule 13G/A, Adage Schedule 13G, Great Point Schedule 13G/A. These are selected disclosed positions, not a complete ownership census. Managers and individual co-filers are not additional separate holdings.

Great Point illustrates why the footnotes matter. Its detail identifies 944,292 common shares and 3,131,776 underlying warrant shares, but only 53,047 warrant shares exercisable within the stated 9.99% cap, while the cover aggregate of 4,076,068 combines the broader quantities with the capped percentage. Treating all 4.076 million as issued common held by the manager would misstate the share structure.

The company’s official coverage roster lists Brookline Capital Markets/Kemp Dolliver, Guggenheim Partners/Vamil Divan, H.C. Wainwright and Maxim Group/Jason McCarthy. Merlintrader has not located an original dated analyst report with a verifiable price target, so no individual firm’s target is reproduced. After a reverse split, a mechanically adjusted target is not a new analyst opinion. Official analyst coverage.

15 Market structure and retail sentiment

At the October 1, 2026 close of $5.37, the 9,949,609 issued common shares imply a market capitalization of about $53.4M, a Merlintrader calculation on issued common only. The June 30 liquidity of $71.1M carries a different date and should not be netted against it without allowing for third-quarter spending. Finviz data as of October 2 showed 9.95M rounded shares outstanding and a 9.56M float. Short interest was 459,745 shares at the September 15, 2026 settlement date, the latest published as of October 2 in Nasdaq short-interest data reported through FINRA, about 4.81% of that float. Finviz screener data as of October 2 also showed institutional ownership of 56.33% and insider ownership of 3.96%: third-party aggregates that differ from the SEC filings in the previous section and do not establish current positioning.

What retail traders discussed, September 29 to October 2, 2026

Sampled messages from September 29 to October 2 focused on Phase 1 timing, with several posters naming release days the company has not announced. One poster pointed out that the pending SCY-770 data come from healthy volunteers rather than ADPKD patients; another read the BARDA award as a sign that IV data had already been seen, an inference no company document supports. These are comments by non-professional traders, from a small sample with repeated participants, so they are not used to estimate broad investor conviction. A narrative that cites only the $214M ceiling, and not the $18.5M base and cost sharing, can run ahead of the evidence.

Stocktwits SCYX snapshot and discussion · Finviz structural data, October 2 · SEC capital structure

16 Risk map and red flags

Clinical risk: an acceptable healthy-volunteer safety profile does not establish efficacy or long-term tolerability in people with renal disease or invasive infection. SCY-770’s renal hypothesis, SCY-247’s efficacy and the transition from exposure targets to patient outcomes each require evidence.

Financing and contract risk: the BARDA award is a cost-share arrangement. Option exercises and eligible costs matter, and the company still bears part of development expenditure. The $214M maximum is not cash and cannot simply be added to cash or equity value. Existing pre-funded warrants, common warrants, stock-based awards and the ATM framework mean that non-dilutive program support does not eliminate corporate dilution risk.

Execution and concentration: a lean organization advancing two programs must manage clinical operations, manufacturing, data quality and regulatory work. The new nephrology hires are relevant capabilities, but appointments do not prove execution, and the SCY-770 Phase 1 completion was announced October 6, after its original Q3 window; the separate SCY-247 IV timing remains a disclosure risk.

Partner and commercial risk: GSK controls the BREXAFEMME relaunch. NDA transfer and an updated label are distinct from confirmed market availability, sales uptake or royalty receipts.

Market and reporting risk: microcap liquidity can change abruptly around a headline. The Q2 profit was not an operating profit, an insider award was not an open-market purchase, and a beneficial holding may include warrants; split adjustments and overlapping co-filers make quick comparisons misleading. SEC risk factors and notes · BARDA conditions

17 Monitoring checklist and evidence that would change the thesis

The most useful next update is evidence that converts a conditional plan into completed work. For SCY-247: the IV dataset, infusion tolerability, exposure, dose schedule, the Phase 2 protocol, actual BARDA option exercises and the company’s share of costs. For SCY-770: food-effect and repeated-dose results, dose rationale, enrollment criteria and how imaging changes relate to renal function.

At each reporting date, the key checks are unrestricted liquidity, operating cash flow and milestone payments, BARDA reimbursements kept separate from unrestricted receipts, and a share base recalculated from company filings only, distinguishing common, pre-funded, ordinary warrants, options, RSUs and unallocated plan reserves.

Watch for an actual GSK launch announcement and product revenue before assuming that commercial economics have begun. Check whether the company changes the Phase 2 start windows or the intended early ADPKD readout. For SCY-770, the later disclosure arrived October 6. No SCY-247 IV topline had been released as of October 6; the September 28 release said dosing was complete with analysis ongoing. The Q3 Form 10-Q is the next scheduled disclosure and is expected to carry the redacted BARDA contract. SCYNEXIS news archive · Latest quarterly filing · BARDA development plan

18 Research conclusion

SCYNEXIS combines a newly prioritized ADPKD program with an antifungal asset that has obtained meaningful external development support. BARDA makes the SCY-247 financing pathway more concrete; it does not turn a Phase 1 asset into an approved therapy. SCY-770 remains the lead program, with patient-level renal evidence still ahead. BREXAFEMME adds partner-dependent optionality, not assured near-term cash generation. As of October 2, 2026, the Phase 1 readouts guided to the third quarter had not been published, so the immediate tests are those data and a SCY-770 Phase 2 start within the fourth-quarter window.

The balance sheet provides room to work under management’s current plan, while the capital structure demands attention to per-share economics. The central analytical task is to follow three separate ledgers: clinical evidence, cash actually available and shares or equivalent claims outstanding. Progress in one does not automatically settle the other two. September 28 company update · SEC Q2 financial and operating context